First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients

By Leon Luis   Vázquez Sergio   Gracia José Manuel   Casal Joaquín   Lazaro Martín   Firvida José Luis   Amenedo Margarita   Santome Lucia   Macia Sonia  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 10, 2012-07 ,pp. : 1389-1396

Informa Healthcare

Access to resources Recommend Favorite

Bevacizumab: a potential new option in the treatment of advanced breast or non-small-cell lung cancer

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 22, Iss. 9, 2006-09 ,pp. : 1-4

Adis International

Access to resources Recommend Favorite

The Role of EGFR Tyrosine Kinase Inhibitors in the First-Line Treatment of Advanced Non Small Cell Lung Cancer Patients Harboring EGFR Mutation

By  

Current Medicinal Chemistry, Vol. 19, Iss. 20, 2012-07 ,pp. : 3337-3352

Bentham Science Publishers

Access to resources Recommend Favorite

The Emerging Role of Histology in the Choice of First-Line Treatment of Advanced Non-Small Cell Lung Cancer: Implication in the Clinical Decision-Making

By  

Current Medicinal Chemistry, Vol. 17, Iss. 11, 2010-04 ,pp. : 1030-1038

Bentham Science Publishers

Access to resources Recommend Favorite

New Antiangiogenetic Therapy Beyond Bevacizumab in the Treatment of Advanced Non Small Cell Lung Cancer

By  

Current Pharmaceutical Design, Vol. 21, Iss. 32, 2015-10 ,pp. : 4763-4772

Bentham Science Publishers

Access to resources Recommend Favorite